BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 33729874)

  • 21. Pharmacoepidemiology, Machine Learning, and COVID-19: An Intent-to-Treat Analysis of Hydroxychloroquine, With or Without Azithromycin, and COVID-19 Outcomes Among Hospitalized US Veterans.
    Gerlovin H; Posner DC; Ho YL; Rentsch CT; Tate JP; King JT; Kurgansky KE; Danciu I; Costa L; Linares FA; Goethert ID; Jacobson DA; Freiberg MS; Begoli E; Muralidhar S; Ramoni RB; Tourassi G; Gaziano JM; Justice AC; Gagnon DR; Cho K
    Am J Epidemiol; 2021 Nov; 190(11):2405-2419. PubMed ID: 34165150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Has the door closed on hydroxychloroquine for SARS-COV-2?
    Paul M
    Clin Microbiol Infect; 2021 Jan; 27(1):3-5. PubMed ID: 33096242
    [No Abstract]   [Full Text] [Related]  

  • 23. Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial.
    Gyselinck I; Liesenborghs L; Landeloos E; Belmans A; Verbeke G; Verhamme P; Vos R; Janssens W;
    Trials; 2021 Feb; 22(1):126. PubMed ID: 33563325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safely Administering Potential QTc Prolonging Therapy Across a Large Health Care System in the COVID-19 Era.
    Saleh M; Gabriels J; Chang D; Fishbein J; Qiu M; Mountantonakis SE; Epstein LM;
    Circ Arrhythm Electrophysiol; 2020 Nov; 13(11):e008937. PubMed ID: 33003964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited.
    Gautret P; Lagier JC; Honoré S; Hoang VT; Colson P; Raoult D
    Int J Antimicrob Agents; 2021 Jan; 57(1):106243. PubMed ID: 33408014
    [No Abstract]   [Full Text] [Related]  

  • 26. Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized patients with COVID-19 (ProPAC-COVID): a statistical analysis plan.
    Sivapalan P; Ulrik CS; Lappere TS; Eklöf JV; Shaker SB; Bødtger UCS; Browatzki A; Meyer CN; Weinreich UM; Laursen CB; Biering-Sørensen T; Knop FK; Lundgren JD; Jensen JS
    Trials; 2020 Oct; 21(1):867. PubMed ID: 33081817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.
    Goldman JD; Diaz G; Urba WJ
    Int J Antimicrob Agents; 2021 Jan; 57(1):106174. PubMed ID: 33408020
    [No Abstract]   [Full Text] [Related]  

  • 28. QT Interval Control to Prevent Torsades de Pointes during Use of Hydroxychloroquine and/or Azithromycin in Patients with COVID-19.
    Wu TC; Sacilotto L; Darrieux FCDC; Pisani CF; Melo SL; Hachul DT; Scanavacca M
    Arq Bras Cardiol; 2020 Jun; 114(6):1061-1066. PubMed ID: 32638906
    [No Abstract]   [Full Text] [Related]  

  • 29. Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach.
    Baralić K; Jorgovanović D; Živančević K; Antonijević Miljaković E; Antonijević B; Buha Djordjevic A; Ćurčić M; Đukić-Ćosić D
    Toxicol Appl Pharmacol; 2020 Nov; 406():115237. PubMed ID: 32920000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute QT Interval Modifications During Hydroxychloroquine-Azithromycin Treatment in the Context of COVID-19 Infection.
    Voisin O; Lorc'h EL; Mahé A; Azria P; Borie MF; Hubert S; Ménage E; Guillerm JC; Mourad JJ
    Mayo Clin Proc; 2020 Aug; 95(8):1696-1700. PubMed ID: 32753141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis.
    Fiolet T; Guihur A; Rebeaud ME; Mulot M; Peiffer-Smadja N; Mahamat-Saleh Y
    Clin Microbiol Infect; 2021 Jan; 27(1):19-27. PubMed ID: 32860962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.
    Sarayani A; Cicali B; Henriksen CH; Brown JD
    Res Social Adm Pharm; 2021 Feb; 17(2):483-486. PubMed ID: 32327397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review on the Clinical Pharmacology of Hydroxychloroquine Sulfate for the Treatment of COVID-19.
    Cui C; Tu S; En VSJ; Li X; Yao X; Li H; Liu D
    Curr Drug Metab; 2020; 21(6):427-435. PubMed ID: 32520683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hydroxychloroquine plus azithromycin and early hospital admission are beneficial in COVID-19 patients: Turkish experience with real-life data.
    Tanriverdİ E; Çörtük M; Yildirim BZ; Uğur Chousein EG; Turan D; Çinarka H; Özgül MA; Çetinkaya E
    Turk J Med Sci; 2021 Feb; 51(1):10-5. PubMed ID: 32682360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study.
    Derwand R; Scholz M; Zelenko V
    Int J Antimicrob Agents; 2020 Dec; 56(6):106214. PubMed ID: 33122096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.
    Singh B; Ryan H; Kredo T; Chaplin M; Fletcher T
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013587. PubMed ID: 33624299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Letter to the editor about "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".
    Saad MO
    Int J Antimicrob Agents; 2021 Jan; 57(1):106171. PubMed ID: 33408024
    [No Abstract]   [Full Text] [Related]  

  • 38. Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial.
    Dos Santos MR
    Int J Antimicrob Agents; 2021 Jan; 57(1):106176. PubMed ID: 33408022
    [No Abstract]   [Full Text] [Related]  

  • 39. Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia.
    Mori N; Katayama M; Nukaga S
    J Microbiol Immunol Infect; 2021 Feb; 54(1):109-112. PubMed ID: 33054978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Uncertain effects of hydroxychloroquine and azithromycin on SARS-Cov-2 viral load.
    Nguyen TV
    Int J Antimicrob Agents; 2021 Jan; 57(1):106169. PubMed ID: 33408026
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.